GET A VALUABLE CERTIFICATE FOR JOB MARKET


ACADEMIC RECOGNITION OF 3 OR 6 CREDITS


DESIGNED FOR EXPERTS BY EXPERTS


INTRODUCTION TO BENEFIT-RISK ASSESSMENT AND PHARMACOECONOMICS IN DECISION MAKING


OBJECTIVES



The objective of the module is to gain insight in the role of benefit-risk assessment and pharmacoeconomics in the process of decision-making on medicines by different stakeholders.

At the end of this module, trainees will be able to:

delineate the process of decision-making and the perspectives of the stakeholders involved

explain the rationale of benefit-risk assessment and pharmacoeconomic evaluation

evaluate the methodology and results of benefit-risk and pharmaco-economic studies

translate of the results into the process of decision-making

Benefit-risk assessment, decision making, pharmacoeconomics, communication

 

MODULE PARTS



  1. Introduction
  2. Benefits
  3. Risk/Harms
  4. Principles and methods of comparative benefit-risk assessment
  5. Principles of Pharmacoeconomics

 

TRAINER TEAM



Coordinator: Dr Rianne Van Den Ham (from Utrecht Universiteit)

Expert(s): Prof Olaf Klungel, Prof Anthonius De Boer, Dr Jet Van Der Zijden, Dr Anke Hovels, Dr Rob Heerdink, Dr Susanne Vijverberg (from Utrecht Universiteit), Prof Jan A.m. Raaijmakers (from GlaxoSmithKline Research and Development Ltd).

Introductory level
75 h workload over 3 months (3 ECTS credits)
Key dates
Course calendar
Certificate award
or included in Master Year 2 programme
English language
Online based learning
Student: 1,500 €
Professional: 3,000 €
  Savings could be offered under eligibility conditions.

APPLY NOW

Applications open until September 08th, 2017

Or include this module in your training curriculum choices...

Master Year 2 PhD



Confused? Read the FAQs...

NEED TO TALK TO US?

+33 5 47 30 42 69

Monday-Friday / 9.00am-6.00pm CET

 

Supported By

IMI logo EU logo efpia logo

Created By

Eu2P Partners